author-photo

Corey J. Langer

University of Pennsylvania
Fox Chase Cancer Center
Hospital of the University of Pennsylvania

643

Papers

23739

Citations

Citation Trend

Filter By

Papers (643) Sort By

Journal Conference Others

OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

2021
Show All
- Source
- Cite
- Save
Citations (1)
MA06.01 Death From Intercurrent Disease After Proton- Versus Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic.

2021 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (0)
nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

2021 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Systemic Therapy for Mutation-Driven NSCLC.

2021 Seminars in Radiation Oncology
Show All
- Source
- Cite
- Save
Citations (2)
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer.

2021 Journal of Geriatric Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.

2021 Future Oncology
Show All
- Source
- Cite
- Save
Citations (0)